Ucf-101

• UNSPSC Description:

  Ucf-101 is a selective and competitive inhibitor of pro-apoptotic protease Omi/HtrA2, with an IC50 of 9.5 μM for His-Omi. Ucf-101 exhibits very little activity against various other serine proteases (IC50>200 μM). Ucf-101 has a natural red fluorescence at 543 nm that is used to monitor its ability to enter mammalian cells. Ucf-101 has a significant cardioprotective effect against MI/R injury and also has certain neuroprotective effect[1][2][3].

• Target Antigen:

  Apoptosis

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Field of Research:

  Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/ucf-101.html

• Purity:

  98.06

• Solubility:

  DMSO : 12.5 mg/mL (ultrasonic)

• Smiles:

  O=C(/C(C(N1C2=CC=CC=C2)=O)=C/C3=CC=C(C4=C([N+]([O-])=O)C=CC=C4)O3)N(C5=CC=CC=C5)C1=S

• Molecular Weight:

  495.51

• References & Citations:

  [1]Cilenti L, et, al. Characterization of a novel and specific inhibitor for the pro-apoptotic protease Omi/HtrA2. J Biol Chem. 2003 Mar 28;278(13):11489-94.|[2]Liu HR, et, al. Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion. Circulation. 2005 Jan 4;111(1):90-6.|[3]Li Y, et, al. Ucf-101 protects in vivoandin vitro models of PD against 6-hydroxydopamine toxicity by alleviating endoplasmic reticulum stress via the Wnt/β-catenin pathway. J Clin Neurosci. 2020 Jan;71:217-225.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  313649-08-0